Cancer treatment doesn’t always finish when a patient is in remission. Small numbers of cancer cells may remain in the body and are hard to detect with standard tests. This has led to a need for sensitive methods for detection of minimal residual disease and for monitoring treatment response. As cancer care becomes more focused on each patient, MRD testing is becoming more critical as it can help doctors detect residual disease and make treatment decisions.
What Is Minimal Residual Disease?
A very small number of cancer cells remain in the body after treatment is referred as minimal residual disease (MRD). These cells may not be seen through regular tests because they can be present in very low amounts. Even when a patient shows no clear signs of cancer, these cells may still remain. In different types of cancer, including blood cancers MRD can occur, and its presence can provide useful information about the patient’s condition.
MRD testing helps doctors look for these remaining cancer cells after treatment. It can help track how well treatment is working and check if cancer cells are still present. Detection of MRD can also aid physicians in evaluating the risk of relapse and can support treatment monitoring and inform additional care when necessary. MRD diagnostics are emerging as a key component of cancer monitoring.
Key Growth Drivers
Increasing Cancer Burden and Need for Treatment Monitoring
The rising number of cancer cases is increasing the need for better treatment monitoring. To check if cancer cells remain after treatment doctors need reliable ways. MRD testing can help detect very small amounts of cancer that may not be found through regular tests. Therefore, minimal residual disease testing is useful for monitoring response to treatment and risk of cancer recurrence.
Growing Adoption of Precision Medicine
Based on the needs of each patient, precision medicine focuses on choosing treatment. This approach is increasing the use of tests that provide detailed information about cancer. MRD diagnostics can help doctors understand how a patient responds to treatment. The results may also support decisions about further care. As personalized treatment becomes more common, demand for MRD testing is also growing.
MRD Testing Technologies
Several technologies are used for MRD detection. Flow cytometry is one of the commonly used methods and had a 34.8% market share in 2025. This is a standard part of MRD testing and can find abnormal cells in a sample. Improvements in the tests are also helping doctors find smaller numbers of any cancer cells that are left.
PCR-based testing is another method used for minimal residual disease testing. It can find certain genetic changes associated with cancer cells. This can be helpful when a known marker needs to be followed after treatment. PCR-based methods can give sensitive results and help doctors track whether cancer cells are still around.
In MRD diagnostics next-generation sequencing (NGS) is also gaining attention. The segment is expected to grow at a 16.2% CAGR. NGS gives a more detailed picture of genetic changes and can detect very small amounts of cancer. Its growing use is enabling more sensitive and personalized testing. NGS MRD testing may improve treatment and follow-up care monitoring.
Cancer Applications Driving MRD Testing
MRD testing is widely used in blood cancers such as leukemia and lymphoma. These cancers can leave small amounts of abnormal cells after treatment. Regular monitoring can help doctors see if these cells are still there. Minimal residual disease testing can also help monitor how well a patient is responding to treatment, and can help with follow-up care.
In multiple myeloma, MRD testing helps doctors check the level of cancer cells left after treatment. MRD negativity means that no cancer cells are found by the test at a given level of sensitivity. This can provide useful information about treatment response. To monitor the patient over time doctors may use these results along with other tests.
The use of MRD diagnostics is also expanding in solid tumors. New testing methods are helping researchers look for small amounts of cancer in blood samples. Liquid biopsy and circulating tumor DNA (ctDNA) are being studied for this purpose. During follow-up these methods may help monitor treatment response and detect changes in cancer.
Challenges and Opportunities in MRD Testing
MRD testing faces several challenges that can affect its wider use. High testing costs can make these tests difficult to access, especially in areas where healthcare resources are limited. Reimbursement restrictions can also limit patient access. Variations in testing methods and standards can make results more difficult to compare. For some healthcare centers the need for skilled professionals and advanced laboratory infrastructure can also be a challenge.
At the same time, new opportunities are supporting the growth of MRD testing. Liquid biopsy can offer a simpler way to collect samples and monitor cancer. NGS is getting better at finding small numbers of cancer cells. In solid tumors the use of MRD diagnostics is also expanding. These developments may support wider testing and better treatment monitoring in the future.
Market Outlook, 2026–2034
The minimal residual disease market is expected to grow strongly during 2026–2034. The market is projected to rise from USD 2.38 billion in 2025 to USD 7.20 billion by 2034, at a 13.1% CAGR. This growth is attributed to the increasing demand for better cancer monitoring and more accurate treatment decisions.
NGS, liquid biopsy, and ctDNA testing are expected to support market growth. During treatment these methods can help detect small amounts of cancer cells and track changes. Their use is also expanding beyond blood cancers into solid tumors. As precision oncology continues to grow, MRD testing may become a more standard part of cancer care and follow-up.
FAQs
What is minimal residual disease (MRD)?
MRD means a small amount of cancer remains after treatment. It may not be found through regular tests.
How does MRD testing work?
MRD testing uses blood or bone marrow samples to detect small amounts of cancer cells or cancer-related genetic changes.
Which technology is widely used for MRD detection?
Flow cytometry is widely used for MRD detection, especially in blood cancers. PCR and NGS are also used.
What is the size of the minimal residual disease market?
According to Polaris Market Research, the market was valued at USD 2.38 billion in 2025 and is projected to reach USD 7.20 billion by 2034.
Conclusion
MRD testing is becoming an important tool for cancer monitoring and treatment follow-up. It helps doctors identify small amounts of cancer cells that remain and understand how the treatment is working. The growing use of NGS, liquid biopsy and other testing methods are enabling its role in precision medicine.
To learn more about market growth, trends and key developments, explore the Minimal Residual Disease Market report by Polaris Market Research.
